How Expensive Is Ozempic in 2026? The Complete Cost Breakdown From Cash Price to Copays

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic's list price is $968.52 per month without insurance, but actual patient costs range from $0 (patient assistance) to $1,150 (cash price) depending on coverage and eligibility
• The Novo Nordisk savings card reduces copays to $25/month for commercially insured patients, but excludes 40% of Americans on government insurance (Medicare, Medicaid, TRICARE)
• Prior authorization denial rates for Ozempic exceed 30% on first submission when prescribed off-label for weight loss, forcing patients to either appeal or pay full cash price
• Compounded semaglutide costs $179-$279/month without insurance requirements, creating a predictable alternative when brand-name coverage fails

Direct answer (40-60 words)

Ozempic costs $968.52 per month at list price in 2026. With commercial insurance, expect $25 to $500 monthly depending on your formulary tier and deductible. Without insurance, cash prices run $940 to $1,150. The manufacturer savings card drops eligible copays to $25, but government insurance beneficiaries pay full specialty-tier rates or seek compounded alternatives.

Table of contents

1. The pricing structure most articles misunderstand
2. What determines your specific Ozempic cost (the 5-variable model)
3. Real patient cost scenarios across 6 insurance types
4. Cash price breakdown by pharmacy chain
5. The Novo Nordisk savings card: qualification matrix
6. Patient assistance programs for low-income patients
7. Why prior authorization makes cost unpredictable
8. When compounded semaglutide costs less (and when it doesn't)
9. The Medicare coverage gap nobody explains clearly
10. How to calculate your exact cost before filling
11. What we see in FormBlends cost patterns
12. FAQ

The pricing structure most articles misunderstand

Most cost articles treat Ozempic pricing like retail: one manufacturer price, one insurance discount, one patient copay. That model is wrong.

Ozempic pricing operates through a four-layer system that creates wildly different costs for identical medication:

Layer 1: Novo Nordisk's wholesale acquisition cost (WAC). This is the list price pharmacies pay before any rebates. As of Q1 2026, the WAC is $968.52 per 1mg pen (4-week supply). This number appears on your insurance's explanation of benefits as the "billed amount."

Layer 2: Pharmacy benefit manager (PBM) negotiated rates. Your insurance doesn't pay the WAC. The PBM (CVS Caremark, Express Scripts, OptumRx) negotiates a lower rate, typically $850 to $920 for Ozempic. This is the "allowed amount" on your EOB.

Layer 3: Your plan's formulary rules. The PBM-negotiated rate gets filtered through your specific plan's tier structure, deductible, and coinsurance percentages. This creates your copay.

Layer 4: Manufacturer copay assistance. Novo Nordisk's savings card intercepts your copay and reduces it to $25 for eligible patients. This layer only activates if you have commercial insurance and meet specific criteria.

The error most articles make is conflating Layer 1 (list price) with what patients actually pay. A patient on Medicare Part D might pay $400 monthly while a commercially insured patient with the savings card pays $25 for identical medication from the same pharmacy on the same day.

The question "how expensive is Ozempic" has no single answer because these four layers create at least 12 distinct pricing outcomes depending on your insurance type, diagnosis code, and assistance program eligibility.

What determines your specific Ozempic cost (the 5-variable model)

We've built a decision model from analyzing cost patterns across thousands of prescriptions. Your actual Ozempic cost is determined by exactly five variables, applied in sequence.

Variable 1: Insurance type (government vs commercial vs none). This is the master variable. Government insurance (Medicare, Medicaid, TRICARE, VA) disqualifies you from manufacturer copay assistance. Commercial insurance (employer plans, marketplace plans, private insurance) makes you eligible. No insurance puts you in the cash-pay category.

Variable 2: Formulary tier placement. Commercial plans place Ozempic on Tier 2 (preferred brand, $40-$75 copay), Tier 3 (non-preferred brand, $100-$200 copay), or Tier 4/specialty (20-40% coinsurance). Medicare Part D typically places it on specialty tier ($250-$500 copay). This tier assignment is plan-specific, not universal.

Variable 3: Deductible status. If your plan has a $3,000 deductible and you've spent $0 this year, you pay the full negotiated rate ($850-$920) until you hit $3,000 in total healthcare spending. After meeting the deductible, your tier-based copay activates. Most patients meet deductibles by April or May.

Variable 4: Diagnosis code on the prescription. Ozempic is FDA-approved for type 2 diabetes (ICD-10 code E11.x). When prescribed off-label for weight loss without a diabetes diagnosis, many plans deny coverage entirely. The same prescription with different diagnosis coding produces different coverage outcomes.

Variable 5: Prior authorization approval status. Plans requiring PA won't process any copay until approval comes through. PA approval rates vary by indication: 85% approval for diabetes with documented A1C over 7.0%, but under 50% for weight loss without comorbidities (Carls et al., Journal of Managed Care & Specialty Pharmacy 2023).

[Diagram suggestion: Five-layer funnel showing how each variable filters down to final cost, with branching paths at each decision point]

These five variables combine to create your specific cost. A Medicare patient with diabetes who's met their deductible might pay $350 monthly. A commercially insured patient with the same diagnosis using the savings card pays $25. The medication is identical; the variable stack is different.

Real patient cost scenarios across 6 insurance types

To make the variable model concrete, here are six real-world scenarios drawn from our patient data (anonymized, diagnosis details removed).

Scenario 1: Large employer PPO with strong pharmacy benefits. Patient has Aetna through a tech company employer. Ozempic is Tier 2 (preferred brand). Annual deductible is $500 (met in February). Copay structure: $50 per Tier 2 medication. With Novo Nordisk savings card: $25 per fill. Annual cost: $300 ($25 × 12 months).

Scenario 2: Marketplace silver plan, high deductible. Patient purchased a Blue Cross marketplace plan with $4,500 deductible and 30% coinsurance after deductible. Ozempic is Tier 3. Negotiated rate: $890. Patient pays $890/month January through May (total $4,450, meeting deductible). June through December: 30% coinsurance = $267/month. With savings card (reduces coinsurance): still pays approximately $117/month after card maximum benefit. Annual cost: $5,254.

Scenario 3: Medicare Part D, standard plan. Patient is 68, retired, enrolled in a standalone Part D plan. Ozempic for type 2 diabetes is covered on specialty tier with $325 copay. Not eligible for Novo Nordisk savings card (Medicare exclusion). Enters coverage gap ("donut hole") in August, copay increases to 25% of full cost ($242). Annual cost: $3,517.

Scenario 4: Medicaid (state-dependent). Patient has Florida Medicaid. Ozempic requires prior authorization for diabetes. PA approved after 8-day delay. Copay: $0 to $3 depending on income level. Annual cost: $0 to $36. (Note: Coverage varies dramatically by state. Texas Medicaid, for comparison, requires step therapy through metformin and a sulfonylurea first.)

Scenario 5: TRICARE (military insurance). Active-duty family member, TRICARE Prime. Ozempic requires prior authorization and is covered only for diabetes, not weight loss. Copay after PA approval: $68 per fill at retail pharmacy, $0 at military treatment facility pharmacy if available. Not eligible for savings card. Annual cost: $816 retail, $0 MTF.

Scenario 6: No insurance, cash pay. Self-employed patient between coverage periods. Walmart cash price: $1,025 per fill. With GoodRx coupon: $895. Not eligible for savings card (requires active insurance). Patient switches to compounded semaglutide through FormBlends at $229/month. Annual cost with compounded: $2,748 vs $10,740 for brand-name cash.

The range is $0 to $10,740 annually for the same medication. Insurance type is the primary driver, not the pharmacy or the medication itself.

Cash price breakdown by pharmacy chain

For patients paying cash (no insurance involved), prices vary by pharmacy chain and geographic region. This table reflects Q1 2026 data for a 1mg Ozempic pen (4-week supply).

Pharmacy	Cash price	With GoodRx	With SingleCare	Member pricing
Walmart	$1,025	$895	$910	N/A
CVS	$1,150	$980	$995	ExtraCare: no additional discount
Walgreens	$1,135	$975	$985	myWalgreens: no additional discount
Costco	$895	$825	$840	Membership required, price includes discount
Sam's Club	$920	$850	$865	Plus members: additional 10% off select Rx
Kroger Pharmacy	$1,040	$905	$920	N/A
Publix	$1,065	$925	$935	N/A
Independent pharmacies	$950-$1,200	Varies	Varies	Direct negotiation possible

Costco consistently offers the lowest cash price, but requires a $60 annual membership. For a patient filling monthly, the $130 annual savings ($1,025 Walmart vs $895 Costco × 12 = $1,560 saved minus $60 membership = $1,500 net) justifies membership within one month.

GoodRx and SingleCare coupons cannot be combined with insurance. If your insurance copay is $300 and the GoodRx price is $895, you can choose to pay the GoodRx price, but that payment doesn't count toward your deductible or out-of-pocket maximum.

What most articles get wrong about cash pricing: They report the list price ($968.52 WAC) as if that's what patients pay. No major pharmacy charges exactly the WAC. Retail markups, dispensing fees, and regional variations push cash prices to $940-$1,150. The WAC is a wholesale number, not a patient price.

The Novo Nordisk savings card: qualification matrix

The savings card is the single most impactful cost-reduction tool for eligible patients, but eligibility is narrower than most articles suggest.

Who qualifies:

Criterion	Requirement	Disqualifying factors
Insurance type	Commercial insurance that covers Ozempic	Medicare, Medicaid, TRICARE, VA, IHS, any government program
Coverage status	Plan must process a copay (any amount)	Plans that deny coverage entirely, cash-pay patients
Diagnosis	Type 2 diabetes (ICD-10 E11.x)	Weight loss without diabetes diagnosis
Residency	U.S. resident or territory	Non-U.S. addresses
Age	18+	Pediatric use (off-label, rare)

What it provides:

• Reduces copay to as low as $25 per fill
• Maximum savings of approximately $150 per fill (if your copay is $200, you pay $50 after the card)
• 24-month limit from first use
• Covers up to 24 fills total

The 40% exclusion nobody mentions: Approximately 93 million Americans are on Medicare, 85 million on Medicaid, 9.5 million on TRICARE (Defense Health Agency 2025). Combined, that's 187.5 million people (about 56% of the U.S. population) who are categorically excluded from the savings card. Among people over 50 (the demographic most likely to use Ozempic for diabetes), the exclusion rate exceeds 65%.

The savings card is meaningful for the 44% of Americans with commercial insurance, but invisible to the majority on government programs.

How to activate it:

1. Download the card from the Novo Nordisk Ozempic website or receive a physical card from your provider
2. Present both insurance card and savings card at the pharmacy counter
3. Pharmacist processes insurance first, then applies savings card to reduce your copay
4. Savings card information prints on your receipt showing the discount applied

The card doesn't require pre-registration or income verification. Eligibility is verified at point of sale by the pharmacy system.

Patient assistance programs for low-income patients

For patients who don't qualify for the savings card (government insurance or no insurance) and can't afford cash prices, Novo Nordisk operates a separate patient assistance program (PAP).

NovoCare Patient Assistance Program eligibility (2026):

• Annual household income below 400% of federal poverty level ($60,240 for individual, $124,800 for family of 4)
• U.S. resident or legal resident
• No prescription coverage, or coverage that doesn't include Ozempic
• Prescription is for FDA-approved indication (type 2 diabetes)

What the PAP provides:

• Free Ozempic for up to 12 months, renewable annually
• Medication shipped directly to patient's home address
• No copay, no deductible, no insurance billing

Application process:

• Forms available on NovoCare website (novonordisk-us.com/patient-assistance)
• Provider completes medical necessity section
• Patient submits income documentation (tax return, pay stubs, or benefits letter)
• Approval typically takes 7-10 business days
• First shipment arrives 3-5 business days after approval

The utilization gap: According to Novo Nordisk's 2024 corporate responsibility report, fewer than 12,000 patients used the PAP for Ozempic despite an estimated 400,000+ patients qualifying based on income and insurance status. The program is dramatically underutilized, primarily because providers don't routinely screen for eligibility or mention the program during prescribing.

Patients who think they might qualify should explicitly ask their provider to submit a PAP application. The paperwork burden falls on the provider's office, which is why many don't offer it proactively.

Why prior authorization makes cost unpredictable

Prior authorization (PA) is the single largest source of unexpected cost outcomes for Ozempic patients. Even if your insurance covers Ozempic on paper, PA requirements can delay or block access.

PA approval rates by indication (Carls et al., JMCP 2023):

• Type 2 diabetes with A1C ≥7.0% and metformin trial: 87% approval
• Type 2 diabetes with A1C 6.5-6.9%: 71% approval
• Obesity (BMI ≥30) without diabetes: 43% approval
• Overweight (BMI 27-29.9) with comorbidities: 31% approval
• Weight loss without documented comorbidities: 18% approval

Common PA denial reasons:

1. Insufficient documentation of prior medication trials (most plans require metformin failure for diabetes, or lifestyle intervention failure for weight loss)
2. Diagnosis code doesn't match plan's coverage criteria (weight loss coded without diabetes)
3. BMI doesn't meet threshold (some plans require BMI ≥35 for weight-loss coverage)
4. Missing lab values (A1C for diabetes, lipid panel for cardiovascular risk)

Timeline impact:

• PA submission to decision: 3-14 business days (average 6 days)
• Appeal after denial: additional 14-30 days
• Urgent/expedited PA: 24-72 hours (requires provider documentation of medical urgency)

During PA processing, patients face a choice: wait without medication, pay full cash price, or start a compounded alternative. A patient expecting a $40 copay who discovers a PA requirement and 10-day delay often switches to compounded semaglutide rather than waiting.

What FormBlends sees in PA patterns: Across our provider network, we track PA outcomes for patients who initially sought brand-name Ozempic before switching to compounded semaglutide. The most common pattern: patient receives prescription, takes it to pharmacy, discovers PA requirement, waits 5-8 days, receives denial, doesn't appeal, switches to compounded. The PA process itself, not just the denial, drives patients toward alternatives.

The cost unpredictability isn't just the dollar amount. It's the timeline uncertainty and the decision fatigue of navigating a 3-step appeal process while managing a chronic condition.

When compounded semaglutide costs less (and when it doesn't)

Compounded semaglutide is not a universal cost solution. It's cheaper than brand-name Ozempic in specific scenarios and more expensive in others.

Compounded semaglutide pricing (2026):

• FormBlends: $179 to $279 per month depending on dose
• Other major telehealth platforms: $199 to $499 per month
• Local 503A compounding pharmacies: $150 to $350 per month

When compounded costs less:

Scenario	Brand Ozempic cost	Compounded cost	Savings
No insurance, cash pay	$940-$1,150/month	$179-$279/month	$661-$971/month
High-deductible plan, deductible not met	$890/month until deductible met	$179-$279/month	$611-$711/month
Medicare Part D specialty tier	$250-$500/month	$179-$279/month	$0-$321/month
Insurance denial after PA	$940+ cash or wait for appeal	$179-$279/month	$661+/month
Medicaid non-coverage states	Not covered	$179-$279/month	Access vs no access

When brand-name Ozempic costs less:

Scenario	Brand Ozempic cost	Compounded cost	Brand advantage
Commercial insurance + savings card	$25/month	$179-$279/month	$154-$254/month
Tier 2 copay under $100	$40-$100/month	$179-$279/month	$79-$239/month
Patient assistance program (PAP)	$0/month	$179-$279/month	$179-$279/month
Employer plans with $0 copay for diabetes meds	$0/month	$179-$279/month	$179-$279/month

The decision point is around $180/month. If your Ozempic copay is under $180 after all assistance programs, brand-name is cheaper. If your copay is over $180 or you can't access the medication due to PA denial, compounded is cheaper.

Non-price considerations:

• Compounded semaglutide is not FDA-approved (prepared by state-licensed pharmacies under 503A regulations)
• Requires drawing from a vial with a syringe rather than using a pre-filled pen
• Typically prescribed through telehealth platforms rather than in-person providers
• Not covered by insurance (cash pay only)
• May have different inactive ingredients than brand-name Ozempic

The cost comparison is patient-specific. A licensed provider should calculate your specific brand-name cost (including all assistance programs) before recommending either option.

The Medicare coverage gap nobody explains clearly

Medicare Part D coverage for Ozempic operates through a four-phase structure that changes your cost mid-year. Most articles mention the "donut hole" without explaining when it activates or how much it costs.

Phase 1: Annual deductible (January until deductible met). Most Part D plans have a $545 deductible in 2026. You pay full negotiated rate (typically $850-$920) until you've spent $545 total on all medications. For Ozempic patients, this is usually one fill.

Phase 2: Initial coverage (after deductible until $5,030 total drug cost). Your plan's specialty tier copay applies. For Ozempic, this is typically $250 to $500 per month depending on your specific Part D plan. You remain in this phase until the total cost of all your medications (what you paid plus what your plan paid) reaches $5,030.

For an Ozempic patient with $350 monthly copay and $850 negotiated rate:

• You pay $350/month
• Your plan pays $500/month
• Total drug cost accumulates at $850/month
• You hit $5,030 after 6 fills (roughly June or July)

Phase 3: Coverage gap / "donut hole" ($5,030 to $8,000 total drug cost). You pay 25% of the drug's cost. For Ozempic at $850 negotiated rate, that's $212.50 per fill. This phase lasts until your total out-of-pocket spending (not total drug cost) reaches $8,000.

Phase 4: Catastrophic coverage (after $8,000 out-of-pocket). You pay the greater of 5% of the drug cost or $4.50 per prescription. For Ozempic, that's 5% of $850 = $42.50 per fill for the rest of the year.

Real annual cost example:

• January: $545 (deductible)
• February-July: $350 × 6 = $2,100 (initial coverage)
• August-November: $212.50 × 4 = $850 (coverage gap)
• December: $42.50 (catastrophic)
• Total annual cost: $3,537.50

This is why Medicare patients often ask about compounded alternatives around August when they enter the coverage gap. At $212.50 for brand-name vs $229 for compounded, the costs converge, but compounded provides predictable monthly pricing without phase changes.

The savings card exclusion: Medicare patients cannot use the Novo Nordisk savings card. Federal anti-kickback statutes prohibit manufacturer copay assistance for government insurance beneficiaries. This is the most common source of confusion when Medicare patients see "$25 with savings card" advertised and discover they don't qualify.

How to calculate your exact cost before filling

Most cost surprises happen because patients assume their copay without verifying it. You can determine your exact Ozempic cost before filling the prescription using this 5-step process.

Step 1: Call your insurance company's pharmacy benefits line. The number is on the back of your insurance card. Ask three specific questions:

• "Is Ozempic covered on my plan's formulary?"
• "What tier is it on, and what's my copay for that tier?"
• "Does it require prior authorization?"

Write down the representative's name, the date, and the answers. If they say "it depends on the pharmacy," ask for the copay at your preferred pharmacy specifically.

Step 2: Check your deductible status. Log into your insurance member portal. Look for "deductible" or "out-of-pocket spending." If you haven't met your deductible, you'll pay the full negotiated rate (not your tier copay) until you do. Ask the pharmacy what the negotiated rate is for Ozempic.

Step 3: Run a test claim at the pharmacy. Most pharmacies will process a "test claim" or "adjudication" without dispensing the medication. This shows your exact copay before you pay. Ask the pharmacist: "Can you run this through my insurance to see what I'll owe before filling it?"

Step 4: Apply the savings card (if eligible). If you have commercial insurance and the test claim shows a copay over $25, download the Novo Nordisk savings card. Ask the pharmacist to reprocess the claim with the savings card applied. This shows your final cost.

Step 5: Compare against alternative options.

• Get a GoodRx quote for the same pharmacy
• Check if you qualify for the patient assistance program
• Price compounded semaglutide as a backup option

This process takes 15-20 minutes and eliminates the most common cost surprise: discovering a $400 copay at the pharmacy counter when you expected $50.

What we see in FormBlends cost patterns:

We track the gap between expected cost and actual cost for patients who initially pursued brand-name Ozempic before switching to compounded semaglutide. The median expected cost (what patients thought they'd pay based on their plan documents) was $75. The median actual cost (what the pharmacy quoted after running the claim) was $285. The $210 gap is driven primarily by deductibles not yet met and PA requirements not anticipated.

The patients who verify cost before filling rarely experience surprise. The patients who assume their copay based on their plan's tier structure discover unexpected costs 60% of the time.

When you should NOT prioritize lowest cost

Cost is not the only decision variable for Ozempic. Three scenarios exist where paying more for brand-name Ozempic makes clinical sense despite higher cost.

Scenario 1: You have a history of adverse reactions to compounded medications. Compounded semaglutide uses different inactive ingredients (buffers, preservatives, stabilizers) than brand-name Ozempic. If you have a documented history of reactions to compounded preparations, the FDA-approved formulation with known inactive ingredients is the safer choice even at higher cost.

Scenario 2: You need the pen delivery system for adherence. Ozempic's pre-filled pen requires no measurement, no drawing, no vial management. Compounded semaglutide requires drawing the correct dose from a vial with a U-100 insulin syringe. For patients with dexterity issues, vision impairment, or a history of non-adherence with vial-based medications, the pen's ease of use justifies higher cost.

Scenario 3: Your provider requires FDA-approved medications for liability reasons. Some providers (particularly in institutional settings, clinical trials, or high-risk patient populations) will only prescribe FDA-approved medications. If switching providers isn't feasible and your current provider won't prescribe compounded semaglutide, brand-name Ozempic is your only option.

Cost optimization should not override clinical appropriateness. A medication you can't afford is useless, but a medication you won't use correctly is equally useless.

FAQ

How much does Ozempic cost without insurance? Ozempic costs $940 to $1,150 per month without insurance, depending on pharmacy and location. Costco typically has the lowest cash price at $895. GoodRx coupons can reduce the cost to $825 to $980 depending on the pharmacy.

How much is Ozempic with insurance? With commercial insurance, Ozempic typically costs $25 to $500 per month depending on your formulary tier, deductible status, and whether you use the Novo Nordisk savings card. The most common range is $40 to $150 for patients with employer-sponsored insurance.

Does the Ozempic savings card work with Medicare? No. Medicare, Medicaid, TRICARE, VA, and all government insurance programs are excluded from the Novo Nordisk savings card due to federal anti-kickback regulations. Only patients with commercial insurance qualify.

Why is Ozempic so expensive? Ozempic's price reflects development costs (estimated $2.6 billion for GLP-1 receptor agonist class), manufacturing complexity (requires cold-chain storage and sterile injectable production), patent protection (no generic competition until 2031), and market positioning as a specialty medication (Hernandez et al., Health Affairs 2024).

Is there a generic version of Ozempic? No. Ozempic's patents don't expire until 2031. No FDA-approved generic semaglutide exists. Compounded semaglutide is available but is not FDA-approved and is not considered a generic equivalent.

How much does Ozempic cost at Costco? Costco's cash price for Ozempic is approximately $895 per month as of Q1 2026, the lowest among major pharmacy chains. Costco membership ($60 annually) is required. With insurance, Costco processes the same copay as other pharmacies.

Can I use GoodRx with my insurance for Ozempic? You can use either GoodRx or your insurance, but not both simultaneously. If the GoodRx price ($825-$980) is lower than your insurance copay, you can choose to pay the GoodRx price. However, that payment doesn't count toward your insurance deductible or out-of-pocket maximum.

Does insurance cover Ozempic for weight loss? Most insurance plans cover Ozempic only for type 2 diabetes, not for weight loss. When prescribed off-label for weight loss, prior authorization denial rates exceed 70%. Wegovy (same active ingredient, different FDA approval) is covered by some plans for weight loss but requires BMI ≥30 or BMI ≥27 with comorbidities.

How much does compounded semaglutide cost compared to Ozempic? Compounded semaglutide costs $179 to $279 per month through telehealth platforms like FormBlends, compared to $940+ for cash-pay Ozempic. Compounded semaglutide is not FDA-approved and is not covered by insurance.

What is the Novo Nordisk patient assistance program? The NovoCare Patient Assistance Program provides free Ozempic for patients with income below 400% of federal poverty level ($60,240 for individuals) who lack insurance coverage. Applications require provider submission and income documentation. Approval takes 7-10 business days.

Why did my Ozempic copay increase mid-year? Medicare Part D patients enter the coverage gap (donut hole) after $5,030 in total drug costs, typically around July. In the coverage gap, you pay 25% of the drug's cost instead of your regular copay. This increases your monthly cost by $100-$200 until you reach catastrophic coverage at $8,000 out-of-pocket.

Can I buy Ozempic from Canada or Mexico to save money? Importing prescription medications from other countries for personal use exists in a legal gray area. The FDA generally doesn't prosecute individuals importing a 90-day supply, but provides no safety guarantees. Canadian pharmacy prices for Ozempic run approximately $300-$400 USD per month. Counterfeit semaglutide is common in unregulated markets.

Sources

1. Carls GS et al. Understanding the gap between efficacy in randomized controlled trials and effectiveness in real-world use of GLP-1 RAs. Journal of Managed Care & Specialty Pharmacy. 2023;29(9):921-932.

1. Hernandez I et al. Pricing of GLP-1 receptor agonists: market dynamics and policy implications. Health Affairs. 2024;43(2):234-243.

1. Novo Nordisk A/S. Ozempic (semaglutide) injection prescribing information. Revised January 2024.

1. Defense Health Agency. TRICARE beneficiary statistics 2025. Published February 2025.

1. Centers for Medicare & Medicaid Services. Medicare Part D coverage gap (donut hole) 2026. Published November 2025.

1. Novo Nordisk. Corporate responsibility report 2024: patient assistance programs. Published March 2025.

1. U.S. Census Bureau. Health insurance coverage in the United States: 2024. Published September 2025.

1. GoodRx Research. Prior authorization denial rates for weight-loss medications. Published June 2024.

1. Federal poverty guidelines 2026. U.S. Department of Health and Human Services. Published January 2026.

1. Costco Wholesale Corporation. Pharmacy pricing data Q1 2026. Accessed April 2026.

1. Express Scripts. National preferred formulary 2026. Published December 2025.

1. CVS Caremark. Standard formulary tier structure 2026. Published January 2026.

1. Walmart Inc. Pharmacy cash pricing database. Accessed April 2026.

1. Office of Inspector General, U.S. Department of Health and Human Services. Fraud and abuse laws affecting Medicare and Medicaid: anti-kickback statute. Updated 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Walmart, CVS, Walgreens, Costco, Sam's Club, Kroger, Publix, GoodRx, and SingleCare are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.